Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Semax
Beginner tier: 200 mcg, daily · community consensus
Also known as: ACTH(4-10)PGP, Semax peptide
Get an alert when FDA rules on Semax
Follow every legal or FDA change, Semax included. By default, alerts come as one weekly push that names the peptides.
A single dose triples BDNF mRNA in the rat hippocampus within hours (Dolotov et al.)[1]. Semax (ACTH 4-10 analog, Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide approved in Russia for stroke recovery and cognitive disorders since the 1990s. No placebo-controlled randomized trials exist in healthy adults. The cognitive effects last 1 to 3 weeks after you stop dosing, which is the rationale behind short 10 to 20 day cycles. Users chasing sharper focus, better working memory, and sustained neuroplasticity without long-term daily commitment tend to reach for this one over racetams and stimulants.
What Is Semax?
226 PubMed citations and a prescription approval in Russia. That track record separates Semax (Met-Glu-His-Phe-Pro-Gly-Pro, ACTH 4-10 analog) from most peptides in the nootropic category.
The mechanism is centered on BDNF. Dolotov and colleagues confirmed that a single Semax dose at 50 mcg/kg produced a 3-fold increase in BDNF mRNA and a 1.4-fold increase in BDNF protein in the rat hippocampus [1]. A separate group showed binding-specific increases in BDNF protein in the basal forebrain [2]. Beyond neurotrophins, Semax activates dopaminergic and serotonergic systems without touching cortisol, unlike its parent molecule ACTH.
In practice, the community doses 300 to 600 mcg intranasally each morning for 10 to 14 days. Thousands of user reports across r/Peptides, r/nootropics, and Longecity describe improved focus, verbal fluency, and working memory starting within the first few days. The Selank stack (300 mcg of each, intranasal AM) is the most popular combination, adding anxiolytic balance to the dopaminergic stimulation.
Gusev and colleagues followed 110 stroke patients in Russia and found higher plasma BDNF in those given Semax courses. A 2025 study in transgenic Alzheimer's mice showed reduced amyloid plaques [3]. Another 2025 paper in the British Journal of Pharmacology identified a new mu-opioid receptor mechanism for spinal cord injury recovery [4]. The science is expanding, but it still leans heavily on animal models and small Russian clinical samples. No placebo-controlled RCT has been run in healthy adults at any dose.
How Semax Works
Semax is a synthetic analog of ACTH(4-10) with a Pro-Gly-Pro C-terminal extension. It binds melanocortin receptors MC3R and MC4R in the brain without activating adrenal cortisol production. That selectivity is what separates it from full-length ACTH.
The primary action runs through BDNF upregulation. Dolotov's group showed that 50 mcg/kg of Semax produced a 3-fold increase in exon III BDNF mRNA and a 1.4-fold increase in BDNF protein in the hippocampus [1]. TrkB receptor phosphorylation jumped 1.6-fold in the same study. Grigoriev and colleagues confirmed Semax raised NGF levels in the basal forebrain through a separate pathway [2]. The neurotrophin response begins within hours and accumulates across a 10 to 20 day cycle.
The downstream signaling is broad. Semax modulates dopamine and serotonin turnover in the striatum and prefrontal cortex [5]. A genome-wide analysis of Semax in rat focal ischemia identified changes across immune, vascular, and neuroplasticity gene networks [6]. In 2025, a British Journal of Pharmacology paper revealed a previously unknown mu-opioid receptor and FTO deubiquitination mechanism relevant to spinal cord injury recovery [4].
Plasma half-life is only 2 to 3 minutes intravenously. The functional duration, though, runs 20 to 24 hours. That disconnect comes from the BDNF cascade itself; once BDNF and TrkB signaling are triggered, the downstream neuroplasticity changes continue long after the peptide clears the blood.
Semax Benefits
- Semax benefits center on BDNF-driven cognitive performance, neuroprotection, and short-cycle convenience.
- Hippocampal BDNF triples with a single dose. Dolotov and colleagues confirmed 3-fold BDNF mRNA increase and 1.4-fold BDNF protein increase at 50 mcg/kg in rats [1]. TrkB receptor phosphorylation increased 1.6-fold in the same study.
- Approved for stroke recovery in Russia. Gusev and colleagues followed 110 stroke patients in Russia; those given Semax courses had higher plasma BDNF and better daily-function scores (Zh Nevrol Psikhiatr 2018). The neuroprotective indication is backed by the largest clinical dataset for this peptide.
- Cognitive benefits persist 1 to 3 weeks after stopping. That residual effect is consistently cited across thousands of community reports on r/Peptides and Longecity; it is the primary reason users prefer short cycles over continuous dosing.
- Focus and working memory improve within days. Community users describe sharper verbal fluency and sustained attention starting by day 2 to 4, peaking around days 8 to 14 of a cycle.
- No cortisol disruption. Unlike ACTH, Semax does not stimulate the adrenal glands. You get the neurotrophic benefits without hypothalamic-pituitary-adrenal axis interference.
- 2025 preclinical data is expanding indications. Reduced amyloid plaques in transgenic Alzheimer's mice [3] and a new mu-opioid receptor pathway for spinal cord injury [4] suggest the science is catching up to community applications.
Semax: Science vs Community Consensus
BDNF upregulation and neuroprotection are well-supported in rodent and cell models.
Read the evidence (key study, limitations)
Human data is limited to small Russian clinical trials in stroke and cognitive disorder patients; no placebo-controlled RCTs in healthy adults exist. 2025 studies extend preclinical evidence to Alzheimer's transgenic models and spinal cord injury via a newly identified μ-opioid receptor pathway.
Dolotov et al. 2006 (PMID 16996037): Semax regulates BDNF and TrkB in rat hippocampus; Gusev et al. 2018 (PMID 29798983): 110 stroke patients, Semax vs. no-Semax subgroups (not placebo-controlled), higher plasma BDNF and Barthel scores; PMID 41479572 (2025): Semax reduced amyloid plaques in transgenic AD mice; PMID 40692165 (2025, British J Pharmacology): μ-opioid receptor / FTO deubiquitination mechanism for SCI recovery
Majority of evidence from rodent and cell models. Human trials conducted in Russia (stroke, cognitive disorders) with limited published methodological detail. No placebo-controlled RCTs in healthy adults at any dose. Mechanism of prolonged functional duration (20-24h BDNF cascade from 2-3 min plasma t½) is documented but not fully characterized at human doses.
Widely regarded as one of the most reliable nootropic peptides.
Read the reports (what users report 5, common issues 6)
Strong consensus on focus, working memory, and mental clarity. Short cycles with persistent post-cycle benefits are a distinguishing feature.
- Enhanced focus and information retention (most commonly cited)
- Improved working memory and verbal fluency
- Reduced mental fatigue during cognitively demanding tasks
- Anxiolytic effect at lower doses, especially stacked with Selank
- Persistent cognitive benefits for 1-3 weeks post-cycle
- Sleep disruption if dosed after noon (dopaminergic alerting effect)
- Nasal dryness, tingling, or mild burning: intranasal route, typically resolves week 1
- Afternoon fatigue/comedown at doses ≥600 mcg/day
- Irritability and anxiety at high doses or late-day dosing
- Emotional blunting or mental flatness with sustained high-dose use (>600 mcg/day)
- Reduced libido with prolonged high-dose use (anecdotal, minority of users)
Mechanism aligns: BDNF upregulation and dopamine/serotonin modulation explain reported cognitive effects. Science focused on stroke/neurological injury; community applies it to healthy adult enhancement with no direct RCT support for that population. Doses broadly consistent (animal ~100-500 mcg/kg; community 300-600 mcg ≈ 4-8 mcg/kg for 70 kg). Both agree on short cycles (10-20 days) and morning-only timing.
Semax Dosage Guide
Reconstitution math for the standard setup: 5 mg vial plus 2 mL bacteriostatic water gives you 2500 mcg/mL. On a U-100 insulin syringe, 200 mcg is 8 IU, 300 mcg is 12 IU, 400 mcg is 16 IU, 500 mcg is 20 IU.
For pre-made nasal spray (common at 30 mg/10 mL = 3000 mcg/mL), verify the mcg-per-spray on the label before dosing. Spray calibration varies between atomizers.
Morning only. Nothing after noon. The dopaminergic tail will disrupt your sleep if you dose late. This is the single most common correctable complaint in community reports.
Start at 200 mcg. Assess tolerance for 3 days before moving to 300 mcg. The response curve is clear in the community data; 300 to 500 mcg is where most users settle.
If you feel nothing by day 5, check three things. Is the vial refrigerated and under 21 days post-reconstitution? Is the reconstitution volume correct (a dilution error is the most common source problem)? Did you actually dose in the morning on an empty stomach? Advancing to 400 mcg is reasonable after ruling those out.
Stacking with Selank 300 mcg intranasal takes the edge off for users sensitive to the dopaminergic stimulation. That combination is the community default for good reason.
Short 10–20 day cycles match Russian approved clinical protocols and are reinforced by community observation of diminishing returns beyond ~day 14. Proposed mechanism: adaptation of melanocortin receptor signaling and BDNF-TrkB cascade normalization following peak upregulation with continuous agonism. Dopaminergic tolerance may also contribute. No withdrawal syndrome or dependency reported; cycling preserves efficacy, not safety.
- Diminishing focus and cognitive boost after approximately day 12–14
- Increased baseline anxiety not explained by dose or timing changes
- Post-dose fatigue becoming more prominent despite consistent morning dosing
- Sleep disruption emerging without change in timing or dose
Or use the universal Peptide Calculator for any peptide.
Semax Protocols by Goal
Expected: Improved focus, mental clarity, and working memory by days 2-4. Verbal fluency and learning speed improvements most notable in week 2.
Monitor: Monitor for sleep disruption, nasal irritation, and anxiety. If no effect by day 5, verify storage and reconstitution volume.
How to Use Semax
- 1Reconstitute the vial
Add 2 mL of bacteriostatic water to a 5 mg Semax vial. This gives you 2500 mcg/mL. Swirl gently, do not shake. Let the powder dissolve fully before drawing.
- 2Draw your dose
For subcutaneous injection, use a 29 to 31 gauge insulin syringe (U-100). 200 mcg equals 8 IU. 300 mcg equals 12 IU. 500 mcg equals 20 IU. For intranasal, transfer the reconstituted solution to a calibrated nasal atomizer or use a pre-made spray.
- 3Step 3
Subcutaneous route: clean the injection site (abdomen or thigh) with an alcohol swab. Pinch the skin and insert the needle at a 45-degree angle. Inject slowly and withdraw. Rotate injection sites between doses. Onset is approximately 30 minutes.
- 4Intranasal route: clear your nasal passages with saline
Tilt your head slightly forward. Insert the spray tip into one nostril, close the other, press once and inhale gently. For doses above 200 mcg, split across both nostrils with a 5-minute pause between sides. Onset is approximately 15 minutes.
- 5Time it right
Dose in the morning, before 10 AM. Do not dose after noon. The dopaminergic alerting effect lasts 20 to 24 hours at the functional level.
- 6Store properly
Refrigerate the reconstituted vial at 2 to 8 degrees C. Use within 21 days. Keep unreconstituted lyophilized powder refrigerated for long-term storage.
Alternative Routes
Typical 300–600 mcg/day in 1–2 administrations; onset ~15 min. No formal bioequivalence data vs subQ.
Convenient: no injection required. Commercial research-grade nasal sprays available. Requires sterile, pH-buffered formulation. Nasal dryness and burning common in first week.
Typical 300–800 mcg/day as single AM injection; onset ~30 min. Bioavailability vs intranasal not formally quantified.
Standard insulin syringe technique. Use abdomen or thigh. Preferred when nasal irritation is an issue or when precision dosing is required.
Plasma t½ ~2–3 min IV; clinically lower doses effective. Community protocols do not use IV.
Not recommended outside clinical settings. Context only: this is the route used in PK studies that established the 2-3 min plasma half-life.
Semax Stacking Protocols
Works With
Most popular Semax stack. Semax provides BDNF-driven focus and dopaminergic stimulation; Selank adds GABA/serotonin anxiolysis. Combined effect: cognitive enhancement without the edge, anxiety, or irritability that higher-dose Semax alone can produce. Pre-mixed nasal sprays commercially available.
Semax 300 mcg + Selank 300 mcg intranasal AM; cycle together 10–14 days on / 7 days off
Dual neurotrophic approach: Semax drives BDNF; Noopept promotes NGF and synaptic plasticity. Noopept accumulates over days of use while Semax provides acute focus enhancement.
Semax 300 mcg AM + Noopept 10–20 mg sublingual; lower doses of each to avoid overstimulation
Neurological recovery and brain fog contexts. BPC-157 supports neurotransmitter system repair; Semax drives BDNF and neuroplasticity. Used in post-concussion and TBI recovery protocols.
BPC-157 250–500 mcg AM + Semax 300 mcg AM; 4-week cycles
Bromantane provides dopaminergic/DAT upregulation; Semax handles BDNF and focus. Discussed as an acute cognitive performance ("exam stack") in nootropics communities.
Semax 300 mcg + Bromantane 50–100 mg oral; AM dosing only
Avoid
Semax modulates serotonin systems; additive serotonergic effects possible. Monitor for serotonergic symptoms; dose adjustment of SSRI/SNRI may be needed.
Semax increases dopamine turnover; additive dopaminergic stimulation may cause dysregulation, anxiety, or cardiovascular effects.
Semax is an ACTH analog with melanocortin receptor activity; potential additive effects through shared MC receptor pathways. Combination unstudied.
How much does Semax cost?
Typical price
$3.70 to $6.00 per mg
Middle half of 105 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Semax Side Effects
Sleep disruption is the most consistently reported problem, and it is almost always a timing error. Semax increases dopamine turnover. Dosing after noon delays sleep onset for hours. Restricting administration to before 10 AM resolves the issue for most users. Even a 2 PM dose can wreck that night's sleep architecture.
Anxiety and irritability rank second. The effect is dose-dependent. At 600 mcg per day and above, community reports of agitation, frustration with interruptions, and generalized anxiety increase sharply. Users with pre-existing anxiety disorders face the highest risk. Reducing the dose by 50% typically resolves the issue within 1 to 2 days. Stacking with Selank 300 mcg mitigates anxiety for most users; that combination is the most popular community protocol for exactly this reason.
Nasal irritation affects intranasal users during the first week. Mild burning, tingling, and dryness at the mucosal surface are common and generally self-limiting. A saline rinse between doses helps. For persistent irritation, switching to subcutaneous injection eliminates the local effect entirely.
Afternoon fatigue and a "comedown" feeling appear at doses of 600 mcg per day and higher. Splitting the dose into 2 administrations (morning and before 1 PM) or reducing to 300 to 400 mcg often solves this.
Emotional blunting or mental flatness is reported with sustained use above 600 mcg per day beyond day 14. A minority of users running extended high-dose cycles also report reduced libido. Both effects resolve after stopping.
Hair thinning has been described at very high doses over long periods. The reports are rare and uniformly described as reversible. Melanocortin receptor (MC4R) activation is the speculated mechanism.
Human safety data is limited. The published literature comes from Russian clinical trials in stroke and cognitive disorder patients, not healthy adult nootropic users. No formal adverse event reporting exists for the community dosing context.
Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to ACTH-derived peptides, active intracranial hypertension, history of seizure disorders (limited data, use with caution), and children under 18 without physician supervision. SSRIs and SNRIs require monitoring because Semax modulates serotonin systems; additive serotonergic effects are possible. Dopaminergic drugs (L-DOPA, dopamine agonists) carry additive stimulation risk; dose adjustment may be needed.
Stop use and consult a physician if anxiety persists despite morning-only dosing at 300 mcg or below, if sleep disruption does not resolve with timing changes, or if blood pressure exceeds 130/80 mmHg.
Common Issues & Solutions
Sleep disruption: Semax has a dopaminergic alerting effect. Restrict dosing strictly to before 10am. Even a 2pm dose can delay sleep onset: timing is the most common correctable cause.
Post-dose afternoon fatigue: Reported at doses ≥600 mcg/day. Reduce to 300–400 mcg or split into two smaller doses (AM + early afternoon, not after 1pm) rather than a single large dose.
Nasal irritation: Burning or dryness with intranasal use typically resolves within the first week. Rinse with sterile saline between doses. For persistent irritation, switch to subQ injection.
Anxiety / irritability: Usually dose-dependent. Reduce dose by 50% and reassess. Stacking with Selank 300 mcg mitigates anxiety for most users. If anxiety persists at ≤300 mcg/day, discontinue.
No perceived effects: Verify vial was stored refrigerated post-reconstitution and used within 21 days. Confirm morning-only dosing. Advance from 200 mcg to 400 mcg if no effect by day 5. Also confirm reconstitution volume is correct: under-concentrated vials are a common source issue.
Ask AI about this page
Ask AI for a second opinion on Semax dosing and side effects
Contraindications
- Pregnancy or breastfeeding: no safety data available
- Known hypersensitivity to ACTH-derived peptides
- Active intracranial hypertension
- History of seizure disorders (use with caution: limited data)
- Children under 18 without physician supervision
Drug Interactions
- Melanocortin receptor agonists: potential additive effects through shared receptor pathways
- SSRIs and SNRIs: Semax modulates serotonin systems; monitor for serotonergic effects when combined
- Dopaminergic drugs (L-DOPA, dopamine agonists): Semax increases dopamine turnover; dose adjustment may be needed
- Anticoagulants: limited data; no known interaction but caution advised as Semax has immunomodulatory effects
- Other nootropic peptides (Selank, Noopept): commonly stacked but start with one compound to assess individual response
- Semax is an ACTH analog with melanocortin receptor activity; potential additive effects through shared MC receptor pathways. Combination unstudied.
Product Quality
Semax is one of the most established research peptides with multiple long-running brands and consistent community outcomes. However, it exists entirely in the unregulated research chemical market. Nasal spray formulations carry additional sterility and stability concerns that lyophilized powder does not. Listed as withdrawn from Category 2 as of April 22, 2026. PCAC discussed it on July 24, 2026; compounded pharmacy options with GMP-level controls would need an FDA rule first.
- Third-party COAs showing ≥98% purity by HPLC/MS are the usual benchmark
- For nasal spray: confirm appropriate preservative (benzalkonium chloride or similar) and pH 4.5–6.5
- Lyophilized powder: refrigerate at 2–8°C; reconstituted solution refrigerate and use within 21 days
- Identity testing should confirm the sequence (Met-Glu-His-Phe-Pro-Gly-Pro): degraded Semax is a known quality issue in the market
- Listed as withdrawn from Category 2 as of April 22, 2026. PCAC discussed it on July 24, 2026. Watch for an FDA rule on compounding
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Sleep quality (subjective: diary or wearable) | Throughout cycle, especially first week | Not listed |
| Mood and anxiety (subjective: daily self-assessment) | Weekly during cycle; after any dose change | Not listed |
| Blood pressure | Start of each cycle; if neurological symptoms appear | <130/80 mmHg; no Semax-specific hypertension threshold established |
Dopaminergic alerting effect can disrupt sleep architecture with late dosing; most common reason to adjust timing or reduce dose
Dose-dependent anxiety and irritability are the most common reasons to reduce or discontinue; important to track early to avoid accumulating dysphoria
Precautionary given neurovascular and BDNF-related effects. No documented hypertensive effect in published literature, but data at community doses in healthy adults is limited.
Semax Before and After
Subtle improvements in mental clarity and focus. BDNF upregulation begins within hours of first dose. Some users notice improved attention span on day one.
More consistent cognitive effects. Enhanced verbal fluency and working memory become apparent. Serotonin and dopamine modulation stabilizes.
Peak cognitive benefits. Noticeable improvements in learning speed, memory retention, and mental stamina. BDNF and TrkB receptor upregulation well-established.
Full therapeutic window. Neuroprotective effects accumulate. Many users report sustained focus and reduced mental fatigue throughout the day.
Cognitive benefits often persist for weeks after stopping due to lasting BDNF elevation and neuroplasticity changes. Typical rest period is 1-2 weeks before next cycle.
What to Expect
Days 1 to 3, onset. BDNF upregulation begins within hours of the first dose (Dolotov et al.)[1]. Dopamine and serotonin turnover modulation starts immediately. Community users typically notice subtle improvements in mental clarity and attention span within the first day or two. Some describe a mild stimulatory quality distinct from caffeine. Nasal tingling or light burning is normal for intranasal users during the first week; mild restlessness can occur if timing runs too late in the day.
Days 4 to 7, building effect. The BDNF elevation becomes sustained. TrkB receptor upregulation consolidates. Focus and verbal fluency settle into a more consistent and reliable pattern. Working memory improvements become apparent during this window. Occasional afternoon fatigue may appear at doses of 600 mcg per day and above; some users describe increased frustration with distractions during peak effect hours.
Days 8 to 14, peak window. Maximum BDNF and TrkB receptor engagement based on animal kinetics. This is the phase most community users describe as the best cognitive performance of the cycle. Learning speed, memory retention, and mental stamina all peak. The 10 to 14 day Russian clinical protocol was designed around this window. Emotional blunting or mental flatness can appear at sustained doses above 600 mcg per day; libido changes occasionally surface in a minority of extended-cycle users.
Days 15 to 20, extended phase. Russian approved protocols extend to 20 days. Most community users cycle off at day 14 and report diminishing incremental returns beyond that point. Irritability can increase during this extended window. If the boost feels weaker without any change in dose or timing, receptor adaptation is the likely explanation.
Post-cycle, 1 to 3 weeks off. BDNF elevation and TrkB-driven neuroplasticity changes persist after you stop dosing. Community users consistently report that focus and mood stay raised for 1 to 3 weeks after the last administration. The return to baseline is gradual. This persistent benefit is the primary reason cycling protocols exist; short active phases produce lasting cognitive returns without requiring continuous dosing.
Detailed Timeline: Science vs Community
BDNF upregulation begins within hours of first dose (Dolotov et al., PMID 16996037). Dopamine and serotonin turnover modulation begins immediately. Neurotrophin gene expression changes detectable in animal models within 1-2 hours of administration.
Subtle improvements in mental clarity and focus, sometimes on day one. Increased attention span and task engagement. Mild stimulating quality distinct from caffeine.
Sustained BDNF elevation; TrkB receptor upregulation consolidating. Serotonin and dopamine modulation stabilizes at consistent daily dose.
More consistent and reliable cognitive enhancement. Enhanced verbal fluency and working memory become more apparent. Focus is more sustained throughout the morning.
Maximum BDNF and TrkB receptor engagement based on animal kinetics. Peak neuroplasticity signaling window; aligns with Russian approved 10–20 day clinical cycle design.
Best cognitive performance of the cycle. Noticeable improvements in learning speed, memory retention, and mental stamina. Most users describe this as the optimal phase.
Russian approved protocols run to 20 days. Neuroplasticity accumulation continues but rate of additional benefit likely decreasing.
Most users cycle off at day 14. Those extending to day 20 report diminishing incremental returns after ~day 14. Extended use occasionally associated with increased irritability.
BDNF elevation and TrkB cascade-driven neuroplasticity changes may persist weeks post-administration: the mechanistic rationale for short-cycle protocols producing lasting effects.
Cognitive benefits commonly persist 1–3 weeks after stopping: widely cited as a distinguishing feature of Semax vs other nootropics. Mood and focus remain elevated in the early rest period.
Pharmacokinetics
Source: Plasma t½ ~2-3 min (IV); functional duration 20-24h due to BDNF cascade (Dolotov et al. 2006, PMID 16996037)
Pharmacokinetics: Active Dose Over Time
t½ = ~2-3 min (IV)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Semax Legal?
Semax holds marketing authorization in Russia and Ukraine as a prescription drug for stroke recovery, cognitive disorders, and peptic ulcers. It has no FDA approval and no active IND application in any Western jurisdiction.
Semax was on the FDA Category 2 bulk drug substance list until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed Semax on July 24, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. In the US it is sold online as a research chemical labeled for in-vitro research use.
WADA status is uncertain. Semax is an ACTH analog with melanocortin receptor activity. Athletes subject to drug testing should treat it as a risk and consult their sport's anti-doping authority.
This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research compound.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider Semax
- Individuals seeking cognitive enhancement and improved focus
- Stroke recovery patients (approved indication in Russia)
- Adults with age-related cognitive decline
- Students or professionals needing sustained mental performance
- Patients with dyscirculatory encephalopathy or optic nerve atrophy (Russian indications)
Related Peptides
What Changed for Semax
- Regulatory
PCAC backed Semax for the 503A bulks list 8-5-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.
What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).
Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Semax binds specifically and increases levels of BDNF protein in rat basal forebrain (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Semax reduces amyloid plaque burden in transgenic Alzheimer's disease mice (2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]μ-Opioid receptor/FTO deubiquitination mechanism underlying Semax-induced spinal cord injury recovery (Br J Pharmacol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Semax affects expression of genes related to immune and vascular systems in rat brain focal ischemia (genome-wide analysis) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Comparison of temporal dynamics of NGF and BDNF gene expression under Semax action (opens in a new tab)PubMed 19662538PubMed
- Kinetics of Semax penetration into the brain and blood of rats after intranasal administration (opens in a new tab)Review
- Springer 2025 (DOI: 10.1007/s10517-025-06501-z) (opens in a new tab)PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Semax?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
226 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.